Award winners at the SLAS2026 conference have been announced, with the event attracting a record number of attendees. Steven Finkbeiner from Gladstone Institutes at the University of California San Francisco won the coveted Innovation Award for work on the ‘Development and Application of AI-powered Label-free Imaging for… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research in women’s health uncovered significant findings related to endometriosis and… Read More
News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW. This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed? The top stories: Discovery reveals endometriosis is not… Read More
Cellular ageing could be reprogrammed back towards health, new research finds. A study published in Proceedings of the National Academy of Sciences (PNAS) shows precise modulation of individual transcription factors can reverse core hallmarks of cellular ageing and restore tissue function in vivo. The analysis was led by biotechnology company Junevity,… Read More
Scientists have found a way to combine a precision drug therapy with an antibody and radiation to eliminate tumours without causing side effects. “This is a one-two punch,” said Charly Craik, Professor of Pharmaceutical Chemistry at University of California, San Francisco (UCSF) and co-senior author of the… Read More
Researchers from the University of California, San Francisco (UCSF) shared new data on foundational prostate cancer antigen research at the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago. Prostate cancer’s low mutation burden has resulted in very few druggable neoantigens –… Read More
BioGenCell has partnered with the University of California San Francisco (UCSF) as part of the company’s Phase II clinical trials. The partnership will focus on the impact of BioGenCell’s treatment on those with chronic limb-threatening ischaemia (CLTI also known as CLI), a debilitating condition commonly associated… Read More
